<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="371646">
  <stage>Registered</stage>
  <submitdate>12/10/2016</submitdate>
  <approvaldate>14/10/2016</approvaldate>
  <actrnumber>ACTRN12616001439437</actrnumber>
  <trial_identification>
    <studytitle>Application of nasal sprays for treatment of allergic rhinitis and changes in local gene expression </studytitle>
    <scientifictitle>Mapping allergic rhinitis networks: comparative analysis of the effects of a topical antihistamine, topical nasal steroid and combined antihistamine and steroid on immune phenotype in allergic rhinitis </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>allergic rhinitis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Allergies</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Allocation to one of three nasal sprays. Twice daily application (one spray per nostril) for 7 days. 

The nasal sprays include:
(A) an intranasal antihistamine (Azep; Azelastine hydrochloride 125 mcg/spray)
(B) an intranasal steriod (Flixonase; Fluticasone proprionate 50mcg/spray)
(C) an intranasal antihistamine and steriod combination (Dymista: Azelastine hydrochloride and Fluticasone proprionate 125/50 mcg per spray). 

Compliance will be monitored with return and weighing of spray bottle and self-report in daily symptom and medication diaries
</interventions>
    <comparator>Comparing the effects of three sprays</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Gene expression profiles in nasal mucosal cells following nasal spray administration. This will be assessed using the Nanostring ncounter platform using the PanCancer immune profiling kit (770 genes involved in immune and inflammatory pathways).</outcome>
      <timepoint>The intervention period is 7 days. Primary endpoints will be determined prior to administration at baseline (day 0)  and at the end of treatment (day 7).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Gene expression profiles in blood following nasal spray administration.. This will be assessed using the Nanostring ncounter platform using the PanCancer immune profiling kit (770 genes involved in immune and inflammatory pathways).</outcome>
      <timepoint>The intervention period is 7 days. Primary endpoints will be determined prior to administration at baseline (day 0)  and at the end of treatment (day 7).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For inclusion into the study participants will: have a more than 2 year history of allergic rhinitis, have moderate/severe persistent allergic rhinitis based on ARIA classification, score 5 cm or greater on a visual analogue scale of symptom severity, score 6 or greater on a total nasal symptom score survey, have a positive skin prick test and/or radio-allergosorbent test to Dermatophahoides pteronyssinus or D. farnae. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Participants will be excluded from participating if they: have non-allergic rhinitis, test negative on skin prick test to Dermatophagoides pteronyssinus or D. farnae, have consumed probiotics or prebiotics in the previous 12 weeks, have undergone treatment with systemic corticosteriods in the previous 6 months, use immune-modulating medications, have history of respiratory diseases such as asthma, COPD or other medical conditions such as glaucoma or hepatic impairment, reports excessive alcohol consumption, have history of nasal polyposis, nasal ulcers, recent nasal surgery or nasal trauma, are pregnant, have current illness with bacterial or viral infection, have known hypersensitivity to Azep, Flixonase or Dymista .  </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation concealed - sealed opaque envelopes
</concealment>
    <sequence>Stratified allocation based on sensitivity to allergens (dust mite only vs dustmite and grass allergy), gender and age. Simple randomisation table - computer software </sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Pharmacodynamics</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>11/10/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>48</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Griffith University</primarysponsorname>
    <primarysponsoraddress>Gold Coast Campus
University Drive
Southport 
QLD 4222
</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Meda Pharmaceuticals Pty Ltd</fundingname>
      <fundingaddress>Meda Pharma GmbH &amp; Co. KG
Benzstrasse 1, 61352 Bad Homburg,</fundingaddress>
      <fundingcountry>Germany</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>QLD Allergy Services Clinic </sponsorname>
      <sponsoraddress>Pacific Private Hospital
Level 5, Suite 4
123 Nerang street
Southport, QLD, 4215</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Antihistamines and intranasal steroid sprays are considered first line pharmacological treatment options for alleviating symptoms of allergic rhinitis. The aim of this research is to examine any link between corticosteroid vs antihistamine vs combined corticosteroid and antihistamine administration and local gene expression patterns which may reveal biological pathways involved in each treatment type . </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Griffith University Human Research Ethics Committee</ethicname>
      <ethicaddress>Office for Research
Bray Center N54_0.15
Griffith University - Nathan Campus
Kessels Road
Nathan 4111
QLD </ethicaddress>
      <ethicapprovaldate>11/10/2016</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Amanda Cox</name>
      <address>Griffith University
Gold Coast Campus
G40_9.17
Parklands Drive
Southport
QLD 4222</address>
      <phone>+61 07 5678 0898</phone>
      <fax />
      <email>a.cox@griffith.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Nicholas West</name>
      <address>Griffith University
Gold Coast Campus
G40_9.17
Parklands Drive
Southport
QLD 4222</address>
      <phone>+61 07 5678 0899</phone>
      <fax />
      <email>n.west@griffith.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Amanda Cox</name>
      <address>Griffith University
Gold Coast Campus
G40_9.17
Parklands Drive
Southport
QLD 4222</address>
      <phone>+61 07 5678 0898</phone>
      <fax />
      <email>a.cox@griffith.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>